GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novavax Inc (MEX:NVAX) » Definitions » Cyclically Adjusted PS Ratio

Novavax (MEX:NVAX) Cyclically Adjusted PS Ratio : 1.07 (As of Jul. 08, 2025)


View and export this data going back to 2020. Start your Free Trial

What is Novavax Cyclically Adjusted PS Ratio?

As of today (2025-07-08), Novavax's current share price is MXN123.89. Novavax's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was MXN115.92. Novavax's Cyclically Adjusted PS Ratio for today is 1.07.

The historical rank and industry rank for Novavax's Cyclically Adjusted PS Ratio or its related term are showing as below:

MEX:NVAX' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.82   Med: 14.39   Max: 164.2
Current: 1.25

During the past years, Novavax's highest Cyclically Adjusted PS Ratio was 164.20. The lowest was 0.82. And the median was 14.39.

MEX:NVAX's Cyclically Adjusted PS Ratio is ranked better than
80.61% of 490 companies
in the Biotechnology industry
Industry Median: 5.665 vs MEX:NVAX: 1.25

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Novavax's adjusted revenue per share data for the three months ended in Mar. 2025 was MXN72.139. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is MXN115.92 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Novavax Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Novavax's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novavax Cyclically Adjusted PS Ratio Chart

Novavax Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 50.07 59.42 2.39 1.01 1.62

Novavax Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.99 2.53 2.54 1.62 1.22

Competitive Comparison of Novavax's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Novavax's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novavax's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Novavax's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Novavax's Cyclically Adjusted PS Ratio falls into.


;
;

Novavax Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Novavax's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=123.89/115.92
=1.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novavax's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Novavax's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=72.139/134.9266*134.9266
=72.139

Current CPI (Mar. 2025) = 134.9266.

Novavax Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 16.383 100.684 21.955
201509 8.181 100.392 10.995
201512 7.458 99.792 10.084
201603 5.375 100.470 7.218
201606 3.422 101.688 4.541
201609 4.610 101.861 6.106
201612 8.209 101.863 10.874
201703 7.801 102.862 10.233
201706 8.587 103.349 11.211
201709 10.226 104.136 13.250
201712 12.928 104.011 16.771
201803 10.408 105.290 13.338
201806 11.262 106.317 14.293
201809 7.569 106.507 9.589
201812 6.277 105.998 7.990
201903 3.779 107.251 4.754
201906 2.747 108.070 3.430
201909 2.034 108.329 2.533
201912 5.914 108.420 7.360
202003 1.783 108.902 2.209
202006 13.994 108.767 17.360
202009 56.354 109.815 69.241
202012 -52.477 109.897 -64.429
202103 125.170 111.754 151.124
202106 80.039 114.631 94.210
202109 49.199 115.734 57.358
202112 -196.919 117.630 -225.875
202203 149.169 121.301 165.925
202206 47.867 125.017 51.661
202209 161.463 125.227 173.970
202212 70.285 125.222 75.732
202303 -1.345 127.348 -1.425
202306 69.921 128.729 73.287
202309 3.716 129.860 3.861
202312 34.706 129.419 36.183
202403 11.133 131.776 11.399
202406 45.894 132.554 46.716
202409 10.397 133.029 10.545
202412 11.489 133.157 11.642
202503 72.139 134.927 72.139

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Novavax  (MEX:NVAX) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Novavax Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Novavax's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Novavax Business Description

Industry
Address
700 Quince Orchard Road, Gaithersburg, MD, USA, 20878
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.